Unbiased Analysis of Today's Healthcare Issues

Archive for the 'Public Policy' Category

How do we measure the value of and pay for biomedical innovation?

Dana Goldman, Samuel Nussbaum, and Mark Linthicum have an interesting post on the Health Affairs blog about innovation, value measurement and pricing.  The article mentions the new Innovation and Value Initiative, where I serve as the Director of Research.  An excerpt is below. New pricing mechanisms are needed to effectively link prices to value; we […]

Read the rest of this entry »

Is Precision Medicine ready for prime time

According to two researchers, the answer is no.  As they write at Stat: As we wrote recently in Science, three key barriers are impeding the drive toward truly transformational precision medicine: researchers often don’t rigorously test the biological theories that supposedly explain why a targeted treatment should work; they haven’t fully determined the accuracy of the diagnostic […]

Read the rest of this entry »

The coming U.S. debt crisis

The Congressional Budget Office provides some gloomy news on the fiscal health of the federal government in their recent 2016 Long Term Budget Outlook.  They state: If current laws governing taxes and spending did not change, the United States would face steadily increasing federal budget deficits and debt over the next 30 years, according to projections […]

Read the rest of this entry »

Clinton vs. Trump: A Healthcare Comparison

AJMC has a nice article summarizing some of the key differences between the two presidential candidates.  I paraphrase the article below. The future of the Affordable Care Act (ACA). Clinton wants to keep or even expand the ACA and wants to cap out-of-pocket drug costs.  Clinton has even called for a public option. On the […]

Read the rest of this entry »

Will value-based pricing be coming to the U.S.?

The answer may be yes.  One of the big inpediments to value-based pricing of pharmaceuticals was that any discount given to any single organization based on outcomes needed to be reflected in the Medicaid price.  Since outcomes are subject to random noise, there will inevitably be health plans that end up getting a low price due to worse than expected […]

Read the rest of this entry »

Sounds like a good idea?

Kaiser’s family of website has some interesting posts of late.  The Kaiser Family Foundation presents 10 Essential Facts about Medicare Prescription Drug Spending.  They show the increasing price of U.S. prescription drugs spending over time. They also show that many patients with Medicare Part D, still bear a large share of prescription drug costs for […]

Read the rest of this entry »

Children and Cost-Benefit Analysis

Alan Balch, PhD, discusses the Institute for Clinical and Economic Review’s (ICER’s) Value Assessment Framework tool that aims to provide stakeholders in healthcare with evidence to make more informed decisions regarding new cancer therapies. Dr Balch also considers limitations to the tool’s effectiveness. Plus, he even discusses why if we lived life using a strict […]

Read the rest of this entry »

Gates: US Drug pricing system is ‘Better Than Most’

There has been a lot of criticism of drug prices in the U.S. One person not included the chorus of critics is Bill Gates. In an interview with Bloomberg, he said: “The current system is better than most other systems one can imagine,” Gates said in an interview on Bloomberg Television. “The drug companies are […]

Read the rest of this entry »

Patient perspective on cancer care funding

Improvement in survival (a.k.a. efficiacy) clearly are important, but what other factors matter?  According to a systematic literature review by MacLeod, Harris and Mahal (2016), these factors include: patients favour funding for cancer medicines that improve health outcomes demonstrated by ‘clinical efficacy’ [Oh et al.], ‘prolonged survival’ [Goldman et al., Seabury et al. Lakdawalla et al.] and/or […]

Read the rest of this entry »

Value Framework Guidelines

In recent years, a number of organizations have developed value frameworks to assess new treatments.  These organizations include the Institute for Clinical and Economic Review (ICER), Memorial Sloan Kettering Memorial Cancer Center (Drug Abacus), American Society for Clinical Oncologists (ASCO),  National Comprehensive Cancer Network (NCCN), European Society of Medical Oncology (Magnitude of Clinical Benefit Scale). […]

Read the rest of this entry »